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ABSTRACT
Background: In the last decade, there has been an unprecedented amount of advocacy and
attention surrounding the issue of breast density (BD) in relation to mammography screening. It is
largely unknown what impact notifying women of their BD has had on clinical practice for PCPs. This
systematic review aimed to synthesise evidence from existing studies to understand the impact of
BD notification on primary care practitioners’ (PCPs) knowledge, attitudes and practice implications.
Methods: Empirical studies were identified via relevant database searches (database inception to
May 2020). Two authors evaluated the eligibility of studies, extracted and crosschecked data, and
assessed the risk of bias. Results were synthesised in a narrative form.
Results: Six studies of the 232 titles identified and screened were included. All studies were
undertaken in the United States (US), with 5 conducted post-legislation in their respective states,
and 1 study conducted in states which were both pre- and post-legislation. Five studies were
quantitative including 4 cross-sectional surveys, and 1 study was qualitative. Findings consistently
demonstrated PCPs’ overall lack of knowledge about BD, low level of comfort in discussing and
managing patients in relation to dense breasts, and limited consensus on the most appropriate
approach for managing women with dense breasts, particularly in relation to supplemental
screening.
Conclusions: This review highlights important gaps in PCPs’ understanding of BD and confidence in
having discussions with women about the implications of dense breasts. It identifies the need for
high-quality research and the development of evidence-based guidelines in order to better support
PCPs.

Keywords: breast density; mammography; notification; legislation; primary care; systematic review
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INTRODUCTION

Breast density (BD) refers to the relative amount of fibrous and glandular tissue in a woman's
breasts compared with the amount of fatty tissue, as seen on a mammogram. There are four
categories of breast density as classified by the Breast Imaging Reporting and Data System (BI-RADS)
Atlas:1 almost entirely fatty, scattered areas of fibroglandular tissue, heterogeneously dense, and
extremely dense. The latter two categories (classified as having dense breasts) are estimated to be
prevalent in 40%–50% of women in the breast screening population in the United States (US).2
Dense breast tissue independently increases the risk of breast cancer3 and, through its masking
effect, lowers the sensitivity of mammography which can increase the chance of a cancer going
undetected.4 The latter may lead to a higher frequency of interval cancers, breast cancers that are
diagnosed after a clear mammogram and before a woman’s next mammogram.5

In the last decade there has been an unprecedented amount of advocacy and attention in the US
surrounding the issue of breast density in relation to mammography screening.6 Before this time,
breast density was less frequently discussed in relation to the risk of developing and being diagnosed
with breast cancer. However, as a result of a largely consumer-driven movement highlighting the
importance of informing women about whether they have dense breasts, with the overall intention
of improving healthcare decision-making, breast density legislation has now passed in the majority
of the US. Since the enactment of such legislation,7 women are now routinely notified of their breast
density after each mammogram.

Primary care practitioners (PCPs) are at the forefront of healthcare decision-making with patients.
Their understanding of, and how, they communicate about a wide range of health issues is of the
upmost importance in informing patients’ decisions. Breast density is now one of these many health
issues. With numerous states in the US now recommending that women receive their BD notification
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follow-up with primary care, PCPs along with Obstetrician-Gynaecologists and Radiologists, may be
faced with BD discussions with patients without adequate support and evidence to guide them in
making BD-related recommendations.8 While the exact role of PCPs differs across health systems
internationally, in the US PCPs, Obstetrician-Gynaecologists and Radiologists play a complementary
role in the notification, discussion and recommendations around BD and the issue of supplemental
screening. Radiologists are required by most states to inform women of their breast density and
encourage conversation with their PCP or usual physician.

The issue of breast cancer risk and supplemental screening, in particular, is not straightforward.
Firstly, BD is a risk factor that is not readily modifiable, which may make it challenging for women to
understand what this means for them, and for PCPs to have discussions about risk-based strategies.
Furthermore, while supplemental screening with imaging modalities such as ultrasound and MRI has
been shown to enhance detection of cancer in dense breasts,9 the evidence is lacking to support
long-term outcomes in terms of the rate of advance breast cancer diagnosis and mortality.9-11 The
potential benefit from increased detection of cancers through supplemental screening in women
with dense breasts may not outweigh the associated downsides including false positives,
overdiagnosis and overtreatment of breast cancer.

It is largely unknown what impact legislation for BD notification has had on clinical practice for PCPs,
in particular in relation to their knowledge about BD, how they feel about the legislation and its
implications for discussions with patients, and importantly recommendations for supplemental
screening. This understanding is not only of central relevance for the care of women in the US
moving forward, but is gaining importance for other countries currently considering implementing
similar BD legislation or widespread notification. This systematic review aims to synthesise evidence
from existing studies to understand the impact of breast density notification on PCPs’ knowledge,
attitudes and practice implications.
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METHODS

Review registration: The systematic review’s protocol was prospectively registered with PROSPERO
(an international prospective register of systematic reviews), registration number: CRD42020189628

Search strategy
In consultation with a literature search specialist, a comprehensive list of search terms was
developed and tested for the return of potentially appropriate results (see supplementary material
1). The keywords, phrases and subjects-headings included in the database search strategy was
informed by a similar systematic review on the topic of breast density notification conducted by
study authors12 and was further refined to specifically capture the population and outcomes of
interest. The database search of Cinhal, Embase, Medline, Pre-Medline, PyscINFO, and PubMed was
conducted from database inception to May 2020. A general search of the Cochrane Reviews
database and extensive grey literature search using Google and Proquest to look for conference
presentations and proceedings, dissertations and media, as well as a search in specific international
grey literature databases for government publications and reports was also conducted. After
removing any duplicates, the returned search results were screened by title and abstract
independently by two researchers (BN and TC) for eligible articles. Study eligibility criteria (Box 1)
was used by the authors to guide the selection of appropriate studies. Decisions regarding inclusion
and exclusion of studies were then made independently by the same two researchers (BN and TC)
and any disagreement was carefully discussed to reach consensus.

[Insert: Box 1. Systematic review eligibility criteria]

Criteria of inclusion and exclusion
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Studies were included in the review if they empirically assessed the impact of breast density
notification on PCPs’ knowledge, perceptions, practice or recommendations. No restrictions were
placed on country, year of publication or written language. Studies were excluded if they were
protocols, reviews, editorials or commentaries. Studies were also excluded if they exclusively
assessed the impact of breast density information or notification only on Radiologists, as the
practice implications were deemed to be vastly different to those of PCPs.

Quality assessment and data extraction
All studies that met the inclusion criteria were appraised for study quality (risk of bias) by two
authors (BN and TC) independently using the Joanna Briggs Institute (JBI) critical appraisal tools.13
Based on the scoring of the individual items used in each appropriate checklist, three categories of
study quality (low, moderate, and high risk of bias) were identified according to each study’s
methodological characteristics. In high-quality studies (low risk of bias), the majority of criteria were
fulfilled and done well, while in low-quality studies (high risk of bias), the majority of criteria were
not addressed, unclear or addressed poorly.

Data from the final studies included in the review were extracted by one author (BN) into a
standardised template in Excel and checked by a second author (TC). Results from the studies were
synthesised in a narrative form, as the heterogeneity of the studies did not support the pooling of
results.14

RESULTS
The initial search yielded 400 papers. After removal of duplicates (n=232) and screening by title and
abstract, 10 papers from the search underwent full texts review. Six papers were then identified and
agreed upon for final inclusion (Figure 1).
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[Insert Figure 1. Flow diagram of included studies]

Characteristics of 6 included studies, are summarised in Table 1. There were 5 quantitative studies
including 4 cross-sectional surveys (sample size (N) range=77-362),15-18 and one quasi-experimental
study (N=63)19 assessing a workshop aimed at improving PCP’s knowledge of BD, and increasing
confidence in counselling patients about supplemental screening. The final included study was a
qualitative interview study.20 There were no randomised controlled trials. All studies were
undertaken in the US.15-20 Three of the 6 studies were conducted in Massachusetts16,19,20, and there
were no studies which included a national sample. Five of the studies15-17,19,20 were conducted in
their respective states post-legislation, and one study18 was conducted in states which were both
pre- and post-legislation. The main outcomes of interest across the studies were knowledge,
attitudes and practice implications for PCPs.

Two studies16,20 were of higher quality with a low risk of bias; the other 4 studies15,17-19 had moderate
to high risk of bias, as the overall quality of reporting was deemed to be low. The high-quality studies
included one of the quantitative surveys16 and the included qualitative study16 (see supplementary
material 2).

[Insert: Table 1. Characteristics of included studies]

Results from the studies are narratively synthesised below by PCPs’ knowledge of BD notification
and BD generally, PCPs’ attitudes towards BD notification, and practice implications in relation to BD
notification. Table 2 describes these findings in more detail by individual study.

[Table 2. Key findings summarised by knowledge, attitudes and practice implications]
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PCPs knowledge of BD and BD notification laws
General awareness of BD notification laws and knowledge surrounding the topic of BD was highly
variable across the studies. Two studies17,21 reported just over half of the sample were aware of the
laws and other 3 studies16,18,20 indicated that the majority of the PCPs were aware of the laws.
However, in two of the three studies with higher awareness of the BD notification laws, knowledge
of breast cancer risk was also measured and was notably lower than awareness.15 18

PCPs attitudes towards BD and BD notification laws
There were a wide range of measures used to assess PCPs attitudes towards BD notification law and
the concept of BD generally. In two studies16,20 it was shown that PCPs had mixed feelings about BD
notification laws. In the survey conducted in Massachusetts the year following BD notification
enactment16 it was found that only 38% of PCPs favoured the legislation. The qualitative interview
study20 conducted in Massachusetts around the same time period found that there were mixed
attitudes around the utility of BD laws for patients and PCPs. PCPs in this study had relatively
positive attitudes about how legislation might affect patient engagement, however PCPs also noted
the lack of evidence informing next steps for screening patients with dense breasts and identified
stress and anxiety as a possible negative consequence of informing patients.

In terms of level of comfort about discussing and answering questions about BD, again the findings
were mixed. In two survey studies conducted at similar time points following enactments of BD
notification, one study found only 6% of PCPs in California described themselves as being completely
comfortable,17 while the other study conducted in Massachusetts found that over 80% of PCPs
indicated “some level of comfort” in having these discussions and in answering questions in relation
to density.15 In Maimone et al’s survey,18 conducted across 3 states (one pre-legislation and two-post
legislation) PCPs were also split in their level of “comfort” in answering questions and providing
management advice for patients. In all three studies PCPs highlighted the need for further education
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and training about BD and how to manage patients, with Brown et al,15 finding that PCPs were more
likely to report the need for more education about BD, relative to specialists (p<0.0001).

Two studies16,19 assessed whether PCPs felt a responsibility to counsel women about BD. In the
survey study,16 attitudes were split with less than half PCPs feeling it was their responsibility to
counsel patients and around a quarter being neutral or unsure, believing it was the responsibility of
Radiologists or breast health providers. In the quasi-experimental study,19 in the post-intervention
survey compared to the baseline survey, more PCPs and residents in the intervention group agreed
or strongly agreed that it was their responsibility to counsel women about BD, however this change
was not significant.

Practice implications for PCPs in relation to BD notification
A number of different practice implications for PCPs in relation to BD notification were highlighted
across studies. In the qualitative study20 it was found that PCPs felt that the legislation failed to
contextualise BD into a broader conversation about risk factors for breast cancer, and PCPs were
particularly interested in discussion about modifiable risk factors such as exercise and alcohol intake.
PCPs in this study felt that Radiologists should be the first point of information about BD followed by
additional questions and contextualisation of the results from PCPs. In the survey study by Khong et
al,17 about a quarter of PCPs discussed performing breast cancer risk assessments themselves, while
the remainder referred women to a breast health clinic when they thought a risk assessment would
be beneficial.

In two of the survey studies,15,18 practice implications for PCPs mainly focused on the issue of
discussing and recommending supplemental screening. In the study by Maimone et al,18 there was
large variability in whether PCPs indicated they offered supplemental screening to every patient
with dense breasts and the choice of a particular supplemental screening modality also varied

9

greatly, with most respondents initially choosing digital breast tomosynthesis. Cost to the individual
patient and breast cancer risk model results were the most common factors which most heavily
influenced PCPs’ decision to suggest supplemental imaging. In the study by Brown et al,15 there was
a mix of responses for how they would proceed with management with 49% respondents feeling it
necessary to order supplemental ultrasound, 7% supplemental breast MRI and the remaining 42%
continuing routine screening or gave no clear recommendations. For the same women with
heterogeneously dense breasts, the numbers followed a similar trend (59%, 3% and 13%,
respectively).

It was flagged in a number of studies16-18,20 that PCPs would value additional support and resources
to help alleviate confusion and improve the process of counselling patients about BD and
supplemental imaging, including additional data and literature for PCPs, and patient information
videos or pamphlets.

DISCUSSION

A small literature base exists from which to assess the impact of breast density information and
notification on PCPs in clinical practice. Studies evaluating this issue are mostly low to moderate
quality, with the majority being surveys with modest response rates conducted in the US with
convenience samples. All but one of the studies were conducted in their respective states in the
post-legislation period, with the other study not describing differences between states in the results
despite being conducted across 3 states with varying pre- and post-legislation periods. Despite the
small number of studies, findings from this systematic review highlight PCPs’ overall lack of
knowledge about BD. Although PCPs in states where BD legislation had been enacted the longest
seemed to indicate greater awareness of BD and BD notification laws, there was still limited
knowledge of breast cancer risk. Importantly, finding across the studies also highlighted the low level
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of comfort in discussing and managing patients in relation to dense breasts, and limited consensus
on the most appropriate approach for managing women with dense breasts. This review points to
the need for high-quality research to assess the impact of BD notification on PCPs and how best to
discuss the implications of having dense breasts with women.

Uncertainty and variability on whether PCPs should discuss and recommend risk-based strategies or
only offer supplemental screening was shown in this review. Since discussion about widespread BD
legislation began over a decade ago in the US, the core of the BD notification controversy has largely
been focused on whether or not to offer supplemental screening and if so, what type, to who and
what frequency.22 Given the limited consensus in this area11 and lack of guidelines, outside of
Obstetrician-Gynaecologists and Radiologists, the ordering of supplemental screening modalities for
women with dense breasts may be left up to the discretion of the PCP in individual consultations
with their patients. Findings from the included studies highlight the need for the current uncertainty
and variability around recommendations for supplemental screening to be factored into guidelines
for PCPs. In settings where BD is not routinely notified, any contemplated change to potentially
systematically notify women about their BD should engage PCPs, as well as ObstetricianGynaecologists and Radiologists, as key stakeholders in the decision about such notification. In two
of the included studies16,20, PCPs were split in support for BD notification legislation noting they were
concerned about the current lack of evidence to inform decision-making for next steps and about
providing BD information to patients without a clear course of action. This further highlights the
need to involve PCPs in the initial decision-making process as well as the co-designing of future
research in this area and management strategies.

Additional training opportunities for PCPs may also help to ensure they are provided with education
and support for understanding BD, having discussions and managing women with dense breasts.
Although countries outside of the US do not currently have BD notification through population-
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based screening programs, many private screening services in these countries are notifying women
about their BD. Furthermore, given the recent developments in the US, there is now growing
pressure from key breast cancer advocacy groups to inform women of their BD on a more wide-scale
level.23 Universally, PCPs will need to become more aware and receive training surrounding the issue
of BD, the inconsistencies in current evidence and the implications this has for women to be able to
have confidence in discussions around these topics. For now, PCPs discussions and future research
could be best directed towards discussion of women’s individualised risk factors and the possible
benefits and trade-off for women in regard to options for supplemental screening.

This review has important strengths and limitations. First and foremost, this is the first systematic
review to synthesise the impact that BD notification and legislation has had specifically on PCPs. This
timely contribution to the literature highlights the need for further research and support for PCPs as
they have been shown to be a crucial source of information and support for women in this area.20,24
The review has been reported in accordance with the criteria in the PRISMA statement for
systematic reviews (see supplementary material 3). Due to the variability of the measures used and
reported outcomes in the included studies, authors were unable to conduct a meta-analysis and
pool the effects of the data, and therefore the results are synthesised narratively.14 Furthermore,
the small number of studies which were assessed were at various time-points in different locations
across the US, so all have different notification processes and information about BD that is provided
to both women and PCPs. Lastly, as all studies were conducted in the US where BD is legislated, the
findings may not be generalisable to other healthcare systems. Given the lack of widespread
notification in other countries it is likely that PCPs may have more limited knowledge and feel less
comfortable with discussing BD and managing women with dense breasts.

CONCLUSIONS
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Notwithstanding the limited literature base identified in this review, these studies highlight that
PCPs are impacted by BD notification and they feel uncertain about their knowledge and how to best
to manage their patients. These findings highlight important gaps in current understanding, and
identify the need to develop, in consultation with PCPs and other healthcare professional involved in
BD discussions and management, evidence-based guidelines. Such guidelines and inclusion of this
information in training programs will enable PCPs to be better informed and supported. How PCPs
discuss and manage women in relation to the issue of BD moving forward will significantly impact
the benefit-to-harm trade-off of notifying women.23 This understanding and how to improve it is not
only crucial to support the current care of women in countries which have already implemented BD
notification but also future care of women in countries which may be considering implementing
widespread BD notification.

This would rather be HOW can we inform / train / involve PCPs and try to set up research
regarding this topic in my opinion.

Author contribution statement: BN, KM and NH conceived the study. BN and TC screened title and
abstracts. BN and TC completed the full text read and data extraction. BN completed the data
synthesis with support from TC and NH. BN and TC conducted the risk of bias assessment. BN wrote
the manuscript with input from TC, MB, RF, KM and NH.
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Box 1. Systematic Review Eligibility Criteria
Inclusion

Exclusion

Types of studies

Empirical studies (quantitative and qualitative e.g. surveys,
interviews or focus groups) that consider the impact or
effect of breast density information / notification /
communication / legislation for PCPs

Protocols, review papers,
editorials, commentary /
discussion papers

Population / types of
participants

Primary care practitioners (General practitioners/Medical
doctors, practice nurses/nurse practitioners, physician
assistants in internal medicine, family medicine and
Obstetrics & Gynaecology)
Any type of medical or community setting

Radiologists

Types of setting
Study factor
(intervention)
Outcome factor

Breast density information / notification / communication /
legislation
Knowledge, perceptions, practice or recommendations
impact/effect (including awareness and concerns)
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Table 1. Characteristics of included studies
Study
(author,
year)

State

Pre or Post
implementation
of BD notification
/ legislation

Study aims

Study design

To access physician views
about breast density and their
practices for breast cancer
screening of women with
dense breasts in light of breast
density laws.

Cross-sectional online
and hard-copy survey

Sample

Setting

Main outcome measures*

Overall study
quality†

Quantitative studies
Brown et al,
2019

Casas et al,
2017

Gunn et al,
2018

Sample was
primarily from
New York,
however a few
participants
were from a
number of
other states
(exact states
not explicitly
provided)

Massachusetts

Massachusetts

Post

Post

Post

To improve providers'
knowledge about breast
density risks and notification
legislation and to increase
confidence in counseling
patients about supplemental
imaging.

To describe the perspectives
about the breast density
legislation among PCPs

Quasi-experimental
study including a
pre/post survey

N=155;
PCPs (n=65)
radiologists (n=42)
n=6 geriatrics (n=6)
gynecologists (n=26)
n=14 other (n=14)
missing (n=2)

N=65
provider intervention
group (n=13)
provider referent group
(n=21)

Online, faculty meetings,
and radiology conference
in New York City

N=80 PCPs

Moderate

Attitudes: assessed through three questions: 1)
comfort level discussing BD, 2) self-reported
frequency of discussions about BD with women, and
3) perceived need for more education about BD.

Workshop at Boston
University Medical Center

residents (n=31):
PCPs (n=14)
radiologists (n=17)
*no resident referent
group

Cross-sectional online
survey

Knowledge: assessed by asking whether they were
aware of the BD laws in the state in which they
practiced and whether they were able to correctly
identify the 2–5 times increased risk of breast cancer
associated with dense breasts.

Online administered to
two safety net hospitals in
Boston Massachusetts

Practice implications: assessed by examining two
hypothetical case scenarios regarding supplemental
imaging for women with dense breasts.
Knowledge: assessed by questions developed based
on the results of a needs assessment conducted in
the general internal medicine section, which showed
that none of the 82 providers surveyed could identify
the required components of the Massachusetts
notification and less than half could identify that no
current guidelines recommended the use of
supplemental screening tests based solely on a
finding of dense breasts.
Attitudes: assessed by a range of questions from a
review of the literature and in accord with the
study’s learning objectives.
Knowledge: assessed by 4 questions including 2
questions in relation to a patient vignette, response
options for each question varied.

Low

High

practicing in two
Massachusetts safety-net
hospitals.

Khong et al,
2015

Maimone et
al, 2017

California

Minnesota,
Arizona and
Florida

Post

To investigate primary
physician awareness of the
California Breast Density
Notification Law and its impact
on primary care practice.

Attitudes: assessed by 3 questions with the response
options on a Likert scale from strongly disagree to
strongly agree.

Cross-sectional online
survey

N=77;
internal medicine (n=30)
family medicine (n=36)
OBG (n=7)
missing (n=4)

Online administered to a
single academic medical
facility

Pre (Florida) /
Post (Minnesota
and Arizona)

To survey primary care
providers in an effort to gauge
awareness of and familiarity
with dense breast legislation
and supplemental screening.

Cross-sectional online
survey

N=362;
internal family medicine
(n=214)
family medicine (n=112)
OBG (n=36)

Online administered to
Mayo Clinic (Minnesota,
Arizona, Florida and
satellite clinics)

Post

To understand perspectives on
BD and inform best practices
are implementation

Qualitative interviews

N=7 PCPs

Face-to-face or telephone
with women recruited
from Brigham and
Women’s Hospitalaffiliated practices

Impact on clinical practice: assessed by 3 questions
with the response options on a Likert scale from
strongly disagree to strongly agree.
4 open-ended questions elicited additional
comments and concerns about BD legislation and
inquired what support providers felt was needed to
assist them in dealing with issues arising from the
new law.
Awareness: assessed using yes/no question.

Moderate

Impact on patient concerns: assessed using yes/no,
multiple-choice and select all questions.
Physician comfort level in discussing issues of BD:
assessed using yes/no, multiple-choice and Likertstyle questions.
Knowledge: assessed by a range of common
questions provided to all participants. 6 additional
more detailed questions were presented to those
who endorsed receiving inquiries from their patients
regarding BD.

Moderate

Qualitative study
Klinger et al,
2016

Massachusetts

Qualitative understanding of BD, legislation, and
implications and preferred methods for delivering BD
information to women.

*as reported in the paper.
†As decided on by study authors based on the explicit checklist items in The Joanna Briggs Institute Critical Appraisal Tools (https://joannabriggs.org/critical-appraisaltools) and other important study factors.

High

Table 2. Key findings summarised by knowledge, attitudes and practice implications
Study
(author, year)

PCPs knowledge of BD and BD notification laws

PCPs attitudes towards BD and BD notification laws

Practice implications for PCPs in relation to BD notification

Quantitative studies
Brown et al,
2019

-

Casas et al,
2017

-

Gunn et al,
2018

-

Khong et al,
2015

-

48% of respondents (PCPs and specialists) were unaware of their
state's BD laws
62% were unaware of the increased risk of breast cancer
associated with dense breasts
Compared to specialists, PCPs were: less aware of BD laws
(p<0.0001) and less knowledgeable about the increase in breast
cancer risk with dense breasts (p<0.0001)

-

PCP’s knowledge scores were significantly higher
postintervention compared to baseline (p<0.0001), no further
change at 3-month follow-up (p=0.06)
Primary care residents had significantly higher knowledge scores
postintervention compared to baseline (p<0.0001)
80% of PCPs were somewhat/very familiar with the
Massachusetts legislation
PCPs could not identify all eight components of the specific
mandated elements for notification
41% correctly identified that no current guidelines recommend
supplemental screening solely based only on dense breasts
57% responded to the scenario knowledge question correctly
49% of PCPs were not aware of the BD legislation before taking
the survey

-

-

-

-

67% of all respondents felt they needed more education about BD and
supplemental imaging, with 18% reporting they were "not
comfortable" answering patients BD questions
PCPs were less likely than specialists to report feeling "comfortable"
answering patients BD questions (p<0.0001), less likely to have
discussions about BD with their patients "often" (p<0.0001) and more
likely to report the need for more education about BD, relative to
specialists (p<0.0001)

Compared to baseline, more PCPs (intervention group) postintervention agreed/strongly agreed with 3 attitudes regarding
responsibility to counsel women about BD, comfort in counselling
women about BD (sig increase p=0.03) and knowledge of referring
women with dense breasts for supplemental screening (p=0.02)
PCPs’ perceptions of the BD mandate varied – 38% favoured the
legislation, 38% did not and 24% were neutral
25% of PCPs felt the legislation would promote informed decisionmaking about breast cancer screening
43% felt counselling women about BD is a PCP’s responsibility, 29%
were neutral, and 28% felt it was the responsibility of other clinical
specialties (e.g., radiologists, breast health providers)
6% of PCPs described themselves as “completely comfortable”
discussing BD

Case scenario: 50-year-old woman with a BIRADS1 (normal) screening
mammogram and extremely dense breasts:
49% of all respondents would order supplemental US (38%
immediately, 11% at next screening), 7% would order a supplemental
MRI, 26% would continue routine screening and 16% had no clear
recommendations
When case scenario had heterogeneously dense breast tissue:
59% would order supplemental US (50% immediately), 3% a
supplemental MRI, 26% would continue routine screening, and 13%
had no clear recommendations
Not assessed.

When asked whether BD notification laws has changed the discussion of
mammography results with patients:
42% responded yes, 28% no and 29% neutrally
49% did not feel prepared to discuss requests about dense breasts
85% were somewhat/ very interested in further training on how to
manage women with dense breasts
-

Maimone et al,
2017

-

-

68% respondents were aware of BD notification laws, 32% had
no knowledge of this legislation
41% of residents and fellows, 30% nurse practitioners and
physician assistants, and 27% staff physicians were unaware of
BD laws
21% of respondents were unfamiliar with the concept of
supplemental screening

-

Comfort level in answering questions about BD and providing
management advice varied considerably amongst PCPs: 17% very
comfortable, 36% moderately comfortable, 30% slightly comfortable,
and 17% not comfortable

-

-

49% of PCPs reported rarely answering patient questions regarding
BD letter, and 20% reported never answering questions related to BD
More female PCPs (43%) compared with male PCPs (19%) noticed a
change in patient concern about BD in the past 6 months (p=0.05)
32% indicated referring patients to a breast health clinic to discuss
questions related to their BD after a mammogram
When participants thought a BC risk assessment would be beneficial,
26% reported performing it themselves, whereas 74% referred to a
breast health clinic
75% were interested in attending a BD educational presentation
26% of PCPs indicated they offered examination to every patient with
dense breasts, 47% offered it dependent on unique patient or risk
factors, 15% did not offer supplemental examinations, 11% other
Choice of supplemental screening modality varied greatly – most
(32%) chose digital breast tomosynthesis

-

-

Costs to the patient (20%) and breast cancer risk models (19%) were
the most common choices for influencing factors in suggesting
supplemental imaging
Solution for alleviating confusion/improvement of counselling: a
synopsis of available data/literature for referring providers, followed
closely by informational pamphlets/documents for patients.

Qualitative study
Klinger et al,
2016

-

Overall, PCPs indicated that they were knowledgeable about the
BD law

-

-

-

PCPs had mixed attitudes about utility of BD laws for patients and
providers: PCPs had relatively positive attitudes about how legislation
might affect patient engagement, but noted the main limitation as the
failure to contextualize BD into a broader conversation about risk
factors for breast cancer
PCPs noted and expressed concern over lack of evidence informing next
steps for screening patients with dense breasts, and were concerned
about providing information without a clear course of action
PCPs frequently identified stress and anxiety as possible negative
consequences of informing patients
PCPs recognised the complexity and trade-offs resulting from
limitations of healthcare coverage

-

-

Some PCPs thought women preferred to hear about BD from their
PCP
Most PCPs thought the information should be reported first by the
radiologist face-to-face, with the PCP available to answer additional
questions/contextualise the results
PCPs noted that a video might be a good way to present this
information and should include information about overall risk
PCPs were particularly interested in discussion of modifiable risk
factors like exercise and alcohol intake

Supplementary material 1. Search strategy
OVID Medline

OVID Pre-Medline

OVID Embase

OVID PsycINFO

CINAHL

PubMed

1. breast*.mp
2. mammogr*.mp
3. dens*.ti
4. physician*.mp
5. practition*.mp
6. provider*.mp
7. doctor*.mp
8. clinician*.mp
9. perce*.mp
10. aware*.mp
11. understand*.mp
12. knowledge*.mp
13. attitude*.mp
14. attitude*.mp
15.
recommend*.mp
16. impact*.mp
17. view*.mp
18. expereinc*.mp
19. 1 or 2
20. 4 or 5 or 6 or 7
or 8
21. 9 or 10 or 11 or
12 or 13 or 14 or 15
or 16 or 17 or 18
22. 3 and 19 and 20
and 21

1. breast*.mp
2. mammogr*.mp
3. dens*.ti
4. physician*.mp
5. practition*.mp
6. provider*.mp
7. doctor*.mp
8. clinician*.mp
9. perce*.mp
10. aware*.mp
11. understand*.mp
12. knowledge*.mp
13. attitude*.mp
14. attitude*.mp
15. recommend*.mp
16. impact*.mp
17. view*.mp
18. expereinc*.mp
19. 1 or 2
20. 4 or 5 or 6 or 7 or
8
21. 9 or 10 or 11 or 12
or 13 or 14 or 15 or
16 or 17 or 18
22. 3 and 19 and 20
and 21

1. breast*.mp
2. mammogr*.mp
3. dens*.ti
4. physician*.mp
5. practition*.mp
6. provider*.mp
7. doctor*.mp
8. clinician*.mp
9. perce*.mp
10. aware*.mp
11. understand*.mp
12. knowledge*.mp
13. attitude*.mp
14. attitude*.mp
15.
recommend*.mp
16. impact*.mp
17. view*.mp
18. expereinc*.mp
19. 1 or 2
20. 4 or 5 or 6 or 7
or 8
21. 9 or 10 or 11 or
12 or 13 or 14 or 15
or 16 or 17 or 18
22. 3 and 19 and 20
and 21

1. breast*.mp
2. mammogr*.mp
3. dens*.ti
4. physician*.mp
5. practition*.mp
6. provider*.mp
7. doctor*.mp
8. clinician*.mp
9. perce*.mp
10. aware*.mp
11. understand*.mp
12. knowledge*.mp
13. attitude*.mp
14. attitude*.mp
15.
recommend*.mp
16. impact*.mp
17. view*.mp
18. expereinc*.mp
19. 1 or 2
20. 4 or 5 or 6 or 7
or 8
21. 9 or 10 or 11 or
12 or 13 or 14 or 15
or 16 or 17 or 18
22. 3 and 19 and 20
and 21

S1 AB breast* OR AB
mammogr*
S2 TI dens*
S3 AB physician* OR
practition* OR
provider* OR doctor*
OR clinician*
S4 AB perce* OR AB
aware* OR AB
understand* OR AB
knowledge* OR AB
attitude* OR AB
pract* OR AB
recommend* OR AB
impact* OR AB view*
OR AB experienc*
S5 S1 AND S2 AND S3
AND S4

(((((breast*[Title]) OR
mammogr*[Title])) AND
dens*[Title]) AND
(((((physician*[Title/Abstract])
OR practition*[Title/Abstract])
OR provider*[Title/Abstract])
OR doctor*[Title/Abstract]) OR
clinician*[Title/Abstract])) AND
((((((((((perce*[Title/Abstract])
OR aware*[Title/Abstract]) OR
understand*[Title/Abstract])
OR
knowledge*[Title/Abstract])
OR attitude*[Title/Abstract])
OR pract*[Title/Abstract]) OR
recommend*[Title/Abstract])
OR impact*[Title/Abstract]) OR
view*[Title/Abstract]) OR
experienc*[Title/Abstract])

Supplementary material 2. Study quality assessed using JBI critical appraisal checklists*
Checklist for Cross-sectional (Prevalence) Studies (9-items)
Study (author,
year)

Checklist items

Was the
sample frame
appropriate to
address the
target
population?

Were study
participants
sampled in an
appropriate
way?

Brown et al,
+
2019
Gunn et al,
+
+
2018
Khong et al,
+
+
2015
Maimone et al,
+
+
2017
Checklist for Quasi-Experimental Studies (9-items)
Is it clear in the
study what is
the ‘cause’ and
what is the
‘effect’ (i.e.
there is no
confusion
about which
variable comes
first)?

Were the
participants
included in any
comparisons
similar?

Casas et al,
+
?
2017
Checklist for Qualitative Research (10-items)
Is there
congruity
between the
stated
philosophical
perspective and
the research
methodology?

Is there
congruity
between the
research
methodology
and the
research

Overall study
quality†

Was the
sample size
adequate?

Were the study
subjects and the
setting described
in detail?

Was the data
analysis
conducted with
sufficient
coverage of the
identified
sample?

Were valid methods
used for the
identification of the
condition?

Was the condition
measured in a
standard, reliable
way for all
participants?

Was there
appropriate
statistical
analysis?

Was the response
rate adequate, and
if not, was the low
response rate
managed
appropriately?

?

+

+

N/A

+

+

+

Moderate

?

+

+

N/A

+

+

+

High

?

-

+

N/A

+

+

+

Moderate

?

+

+

N/A

+

?

+

Moderate

Were the
participants
included in any
comparisons
receiving
similar
treatment/care
other than the
exposure or
intervention of
interest?
?

Was there a
control group?

Were there
multiple
measurements of
the outcome both
pre and post the
intervention/exp
osure?

Was follow up
complete and if not,
were differences
between groups in
terms of their
follow up
adequately
described and
analyzed?

Were the outcomes
of participants
included in any
comparisons
measured in the
same way?

Were outcomes
measured in a
reliable way?

Was appropriate
statistical analysis
used?

+/?

?

?

?

-

+/?

Is there
congruity
between the
research
methodology
and the
methods used
to collect data?

Is there congruity
between the
research
methodology and
the
representation
and analysis of
data?

Is there congruity
between the
research
methodology and
the interpretation
of results?

Is there a statement
locating the
researcher
culturally or
theoretically?

Is the influence of
the researcher on
the research, and
vice- versa,
addressed?

Are participants,
and their voices,
adequately
represented?

Is the research
ethical according to
current criteria or,
for recent studies,
and is there
evidence of ethical
approval by an
appropriate body?

Low

Do the
conclusions
drawn in the
research report
flow from the
analysis, or
interpretation,
of the data?

question or
objectives?
Klinger et al,
2016

-

+

+

+

+

+

*The Joanna Briggs Institute. Critical Appraisal Tools. https://joannabriggs.org/critical-appraisal-tools.
†As decided on by study authors based on the explicit checklist items and other important study factors.

-

+

+

+

High

Supplementary material 3. PRISMA Reporting Checklist

# Checklist item

Reported
on page #

1

Identify the report as a systematic review, meta-analysis, or both.

1

2

Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria,
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and
implications of key findings; systematic review registration number.

3

Rationale

3

Describe the rationale for the review in the context of what is already known.

4-5

Objectives

4

Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons,
outcomes, and study design (PICOS).

53

Protocol and registration

5

Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide
registration information including registration number.

5

Eligibility criteria

6

Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered,
language, publication status) used as criteria for eligibility, giving rationale.

6 (Box 1)

Information sources

7

Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify
additional studies) in the search and date last searched.

6

Search

8

Present full electronic search strategy for at least one database, including any limits used, such that it could be
repeated.

6 (Supp.
1)

Study selection

9

State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable,
included in the meta-analysis).

6

Section/topic
TITLE
Title

ABSTRACT
Structured summary

INTRODUCTION

METHODS

Data collection process

10

Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes
for obtaining and confirming data from investigators.

6

Data items

11

List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and
simplifications made.

6-7

Risk of bias in individual
studies

12

Describe methods used for assessing risk of bias of individual studies (including specification of whether this was
done at the study or outcome level), and how this information is to be used in any data synthesis.

7

Summary measures

13

State the principal summary measures (e.g., risk ratio, difference in means).

7

Synthesis of results

Section/topic

14

Describe the methods of handling data and combining results of studies, if done, including measures of consistency
(e.g., I2) for each meta-analysis.

# Checklist item

7

Reported
on page #

Risk of bias across studies

15

Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective
reporting within studies).

N/A

Additional analyses

16

Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating
which were pre-specified.

N/A

Study selection

17

Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at
each stage, ideally with a flow diagram.

7 (Figure
1)

Study characteristics

18

For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and
provide the citations.

7-8
(Table 1)

Risk of bias within studies

19

Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).

8 (Supp.
2)

Results of individual studies

20

For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.

8-11
(Table 2)

Synthesis of results

21

Present results of each meta-analysis done, including confidence intervals and measures of consistency.

8-11

Risk of bias across studies

22

Present results of any assessment of risk of bias across studies (see Item 15).

N/A

Additional analysis

23

Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).

N/A

Summary of evidence

24

Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to
key groups (e.g., healthcare providers, users, and policy makers).

11-12

Limitations

25

Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of
identified research, reporting bias).

13

Conclusions

26

Provide a general interpretation of the results in the context of other evidence, and implications for future research.

13-14

27

Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the
systematic review.

14

RESULTS

DISCUSSION

FUNDING
Funding

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

